Recent developments focus on quarterly earnings calls and financial performance updates for 2026, with detailed transcripts and highlights available for Q1, Q2, and Q3. News coverage includes analysis of earnings performance and market activity related to the company.

• Astrana Health held its Q3 2026 earnings call with detailed transcript and highlights released in early November 2026 [N1][N2].
• The company reported net income of $12.95 million and EPS of $0.26 for Q3 2026 as per the latest 10-Q filing [S2].
• Q3 2026 earnings were noted to lag some expectations according to market commentary [N3].
• Earlier in 2026, Q2 earnings showed positive call highlights released in August 2026 [N5][N6][N7].
• Investor communications have been consistent with quarterly earnings calls and transcripts available for Q1, Q2, and Q3 2026 [N1][N5].

Astrana Health demonstrates operational profitability with net income reported in the latest quarter and maintains liquidity above current liabilities, indicating financial stability. The company’s active engagement with investors through detailed earnings calls and transparent reporting supports clarity in business execution. Positive trends in earnings call highlights and transcripts suggest ongoing business activity and operational momentum.

The absence of detailed industry and sector information limits visibility into competitive pressures and market risks. While liquidity ratios are above 1, the cash ratio indicates that less than half of current liabilities are covered by cash alone, which may pose short-term liquidity considerations. News coverage references variability in earnings performance, highlighting potential execution risks.

The available information does not explicitly detail Astrana Health's competitive advantages or barriers to entry. However, the company's ability to maintain positive net income and liquidity ratios suggests operational stability. The consistent investor communications and detailed financial disclosures may contribute to market confidence, but specific moat characteristics are not disclosed in the provided data.

• Liquidity Risk: Although the current ratio is 1.25, the cash ratio of 0.51 indicates that cash and equivalents cover only about half of current liabilities, which may affect short-term liquidity.
• Earnings Variability: Recent news indicates variability in quarterly earnings performance, suggesting execution risks.
• Limited Public Business Model Detail: Public disclosures lack detailed descriptions of the company’s sector, industry, and specific business operations, limiting comprehensive risk assessment.

• Astrana Health, Inc. is a publicly traded company with ticker ASTH.
• The latest available financial data is from the 10-Q filing for the quarter ended September 30, 2026, filed on November 6, 2026 [S2].
• As of September 30, 2026, the company reported cash and cash equivalents of $396.2 million USD.
• Current assets as of September 30, 2026, were $979.97 million USD, with current liabilities of $786.07 million USD, resulting in a current ratio of 1.25 and a cash ratio of 0.51 [S2].
• Net income for the quarter ended September 30, 2026, was $12.95 million USD, with basic and diluted EPS of $0.26 per share [S2].
• The company has publicly available earnings call transcripts and highlights for Q1, Q2, and Q3 2026, indicating active investor communications [N1][N2][N3][N4][N5][N6][N7].
• Recent news coverage includes detailed earnings call transcripts and highlights, as well as analysis of earnings performance and option activity [N1][N2][N3][N4][N5][N6][N7][N8].
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].